Hoechst Aktiengesellschaft

Hoechst Roussel Pharmaceuticals

Hoeschst Aktiengesellschaft

Hoechst Aktiengesllschaft

Hoechst Aktienegesellschaft

Klaus U Weithmann

Robert R Bartlett

Dirk Seiffge

Bansi Lal

Jurgen Blumbach

Aftab Dawoodbhai Lakdawala

Ramachandra Ganapati Naik

Vilas Narayan Mumbaikar

Werner Thorwart

Rudolf Schleyerbach

Mandakini V Shirole

Rangarajan Vasumathy

Wilfried Schwab

Hiristo Anagnostopulos

Swati Bal-Tembe

Ruth Raiss

Stefan M Ullner

Rolf Graeve

Kalpana Sanjay Joshi

Mandakini Bipin Alreja

Ravishankar Vasumathy

Ellen S Kurtz

Sadagopan Raghavan

Compounds of formula I, ##STR1## and the physiologically tolerable salts thereof, wherein the substituents R.sub.1 -R.sub.4 have the meanings given in the specifications and show an activity against inflammatory conditions.

Arylcycloalkyl derivatives, their production and their use

3, 5-disubstituted and 3, 4, 5-trisubstituted 2-isoxazolines and

Compounds of formula I, ##STR1## wherein the substituents R.sub.1 -R.sub.4 and a have the given meanings and show an activity against inflammatory conditions.

Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and prophylaxis of degenerative joint disorders, of rheumatic disorders accompanied by cartilage breakdown, such as rheumatoid arthritis, joint trauma and chondrolysis as a consequence of prolonged immobilization of the joint, of inflammations, septic shock, disorders with impaired leukocyte adhesion, disorders caused by an elevated concentration of tumor necrosis factor alpha, such as cachexia or Crohn's disease.

Phosphonoacetic acid derivatives and their use for treating degenerative

N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 1 beta is involved. It is used as a pharmaceutical.

Use of leflunomide for inhibiting interleukin 1 beta

N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 1 alpha is involved. It is used as a pharmaceutical.

Use of leflunomide for inhibiting interleukin 1 alpha

The use of leflunomide for inhibiting interleukin 8 N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 8 is involved. It is used as a pharmaceutical.

Use of leflunomide for inhibiting interleukin 8

N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which tumor necrosis factor alpha is involved. It is used as a pharmaceutical.

Use of leflunomide for inhibiting tumor necrosis factor alpha

Pharmaceutical for the treatment of skin disorders A compound of the formula I or II ##STR1## and physiologically tolerable salts of compound of the formula II are suitable for treatment of psoriasis.

Pharmaceutical for the treatment of skin disorders

Novel substituted thiazoles of the formula I ##STR1## in which R.sup.1 is a saturated or unsaturated, straight-chain or branched C.sub.1 -C.sub.5 -alkyl group,

2-substituted 4-(3-alkyl-5-tert.-butyl-4-hydroxyphenyl) thiazoles,

The present invention relates to formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems and to the use of such formulations for the preparation of medicaments which are suitable for curing prostaglandin deficiencies in humans or animal, for example healing or preventing diseases of the gastro-intestinal tract.

Formulations containing unsaturated fatty acids for the synthesis of

The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body by

Method for detecting the antiaggregatory effect of vasoactive

A combination product containing (A) on the one hand a xanthine derivative of the formula ##STR1## in which one of the radicals R.sup.1 and R.sup.3 represents a straight-chain alkyl, .omega.-1)-oxoalkyl or (.omega.-1)-hydroxyalkyl group having 3 to 8 carbon atoms, and the two other radicals R.sup.2 and R.sup.3, or R.sup.1 and R.sup.2 represent straight-chain or branched alkyl groups having 1 to 8 carbon atoms in the position of R.sup.1 and R.sup.3 and 1 to 4 carbon atoms in the position of R.sup.2, the maximum total of carbon atoms in these two alkyl substituents being 10, or of the formula ##STR2## in which R represents an alkyl radical having 1 to 4 carbon atoms, or prodrug forms of the oxoalkylxanthines of the formula I and II or of the hydroxylalkylxanthine of the formula I, or its metabolites, and

Method of using pentoxifylline for treating inflammation

The present invention relates to a pharmaceutical combination product for the induction of labor or for preventing the development of pregnancy, containing

Growing community of inventors

Hofheim am Taunus, Germany

Klaus U Weithmann